Current Overview on Hypercoagulability in COVID-19 Namrata SinghaniaSaurabh BansalGirish Singhania LEADING ARTICLE 04 August 2020 Pages: 393 - 403
Statins, LDL Cholesterol Control, Cardiovascular Disease Prevention, and Atherosclerosis Progression: A Clinical Perspective Lorenzo NestiAlessandro MengozziAndrea Natali Current Opinion 16 December 2019 Pages: 405 - 412
Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection? Fabian Sanchis-GomarCarl J. LavieMarco V. Perez Current Opinion 01 August 2020 Pages: 413 - 418
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Cardiovascular Disease Prevention Jessica ReidKhyatiben RanaRebecca F. Goldfaden Review Article 11 February 2020 Pages: 419 - 429
Pharmacologic Management of Gout in Patients with Cardiovascular Disease and Heart Failure Mallory T. MouradjianMichael E. PlazakSandeep Devabhakthuni Review Article 24 February 2020 Pages: 431 - 445
Effects of Blood Pressure Lowering Agents on Cardiovascular Outcomes in Weight Excess Patients: A Systematic Review and Meta-analysis Emilio Antonio FrancischettiVirginia Genelhu de AbreuEvandro Silva Freire Coutinho Systematic Review 03 January 2020 Pages: 447 - 470
Effectiveness and Safety of Restarting Oral Anticoagulation in Patients with Atrial Fibrillation after an Intracranial Hemorrhage: Analysis of Medicare Part D Claims Data from 2010–2016 Terri V. NewmanNemin ChenInmaculada Hernandez Original Research Article 06 December 2019 Pages: 471 - 479
Evolution of Patients with Pulmonary Arterial Hypertension Starting Macitentan After the Discontinuation of Other Endothelin-Receptor Antagonists: Results of a Retrospective Study Sergio Cadenas-MenéndezPablo Álvarez VegaJosé Manuel Cifrián Martínez Original Research Article 27 December 2019 Pages: 481 - 487
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Haiyan LiYudong WeiJianyong Li Original Research Article Open access 21 February 2020 Pages: 489 - 503
Comment on: Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease Igor VazAshish KumarRajkumar Doshi Letter to the Editor 11 August 2020 Pages: 505 - 505
Author’s Reply to Vaz et al.: “Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease” Yonghui FuWengen ZhuWenfeng He Letter to the Editor 11 August 2020 Pages: 507 - 508
Comment on: “Predictors of Left Ventricular Dysfunction in Friedreich Ataxia in a 16-Year Observational Study” Roger E. Peverill Letter to the Editor 25 July 2020 Pages: 509 - 510
Author’s Reply to Peverill: “Predictors of Left Ventricular Dysfunction in Friedreich’s Ataxia in a 16-Year Observational Study” Francoise PoussetLise LegrandAlexandra Durr Letter to the Editor 25 July 2020 Pages: 511 - 511